| Literature DB >> 4028958 |
G K Tao, D T Harada, M E Kootsikas, M N Gordon, J H Brinkman.
Abstract
A case report of amoxapine-induced tardive dyskinesia following discontinuation of amoxapine therapy is reported. During 68 weeks of therapy, the patient received a maximum of amoxapine 400 mg/d. Six months after amoxapine discontinuation, the patient continued to have symptoms of tardive dyskinesia. These symptoms correlate with the dopamine receptor-blocking property of amoxapine and its metabolites. We propose that amoxapine therapy be monitored for the long-term as well as the short-term adverse effects of dopamine receptor-blockade.Entities:
Mesh：
Substances：
Year: 1985 PMID： 4028958 DOI： 10.1177/106002808501900707
Source DB: PubMed Journal: Drug Intell Clin Pharm ISSN： 0012-6578